MSACL 2019 US Abstract

Self-Classified Topic Area(s): Metabolomics

Metabolomic Profiling of a Large Cohort of Glioblastoma Stem Cell Lines Identifies Pathways Associated with Clinical Outcome

Olga Zaslaver (1), Michelle Kushida (2), Ian Restall (3), Artee Luchman (3), Adam P. Rosebrock (4), Sam Weiss (3), Peter Dirks (2), Amy A. Caudy (1)
(1) University of Toronto, Toronto, Canada. (2) The Hospital for Sick Children, Toronto, Canada, (3) University of Calgary, Alberta, Canada, (4) Stony Brook School of Medicine, Stony Brook, USA

Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704

Olga Zaslaver (Presenter)
University of Toronto

Presenter Bio: Dr. Zaslaver is a Research Associate at the University of Toronto in the Donnelly Centre for Molecular and Cellular Biology and the Department of Molecular Genetics. She uses full scan metabolomics to discover biomarkers and gene function.

Relevant Financial Disclosures (within past 24 months)

Grant/Research Support University of Toronto

Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above.

Conflict mitigation NOT REQUIRED.

Abstract

GBM tumors are driven by a rare stem cell population. In an effort to identify new therapeutic targets for a disease with few available drug therapies, we have profiled the metabolome of patient-derived GBM stem cell lines cultured in vitro with the goal of identifying metabolic pathways. To enable this large-scale project with samples arriving over a period of years, we have developed reliable LC-MS methods and a biologically derived stable isotope reference material to enable comparison across different sample sets. We observe differences among patient-derived lines in levels of metabolites that have been linked to cancer progression in a variety of systems, including alpha-aminoadipate and methylthioadenosine. We correlate these observations with RNASeq data, allowing us to support known cancer drivers and to propose additional genes that regulate cancer-important metabolites.